1. |
|
|
2. |
- Aledort, Louis, et al.
(author)
-
Factor VIII therapy for hemophilia A: current and future issues
- 2014
-
In: Expert Review of Hematology. - : Informa UK Limited. - 1747-4086 .- 1747-4094. ; 7:3, s. 373-385
-
Research review (peer-reviewed)abstract
- Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic use of FVIII in children and adults with severe hemophilia A, and 4) affordability and availability of FVIII products. Improving patient outcomes by increasing the use of FVIII prophylaxis, preventing or eliminating FVIII inhibitors, and expanding access to FVIII concentrates in developing countries are the major challenges confronting clinicians who care for patients with hemophilia A.
|
|
3. |
- Bergqvist, David
(author)
-
Low-molecular-weight heparin versus rivaroxaban in orthopedic surgery
- 2013
-
In: Expert Review of Hematology. - : Informa UK Limited. - 1747-4086 .- 1747-4094. ; 6:2, s. 135-137
-
Journal article (peer-reviewed)abstract
- From the ORTHO-TEP registry on joint replacement arthroplasty (hip and knee) from Dresden, Germany, three periods of different prophylactic regimens have been compared. In the present paper, results from low-molecular-weight heparin and rivaroxaban have been analyzed, with rivaroxaban showing a benefit concerning both effect and side effects. Clinical end points are used, the results being in line with published data from randomized studies. Inclusion in the registry of consecutive patients is important to illustrate generalizability of results obtained in randomized trials. This review discusses the problem with using historical comparisons to draw firm conclusions.
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
|
|
9. |
- Martner, Anna, 1979, et al.
(author)
-
Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
- 2010
-
In: Expert review of hematology. - : Informa UK Limited. - 1747-4094 .- 1747-4086. ; 3:4, s. 381-91
-
Journal article (peer-reviewed)abstract
- Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction chemotherapy. Despite ensuing courses of consolidation chemotherapy, a large fraction of patients will experience relapses with poor prospects of long-term survival. Histamine dihydrochloride (HDC) in combination with the T-cell-derived cytokine IL-2 was recently approved within the EU as a remission maintenance immunotherapy in AML. HDC reduces myeloid cell-derived suppression of anti-leukemic lymphocytes, and aims to unravel a therapeutic benefit of IL-2 in AML by improving natural killer and T-cell activation. A randomized Phase III trial with 320 AML patients in CR demonstrated a significant reduction of relapse risk after immunotherapy with HDC plus low-dose IL-2 in the post-consolidation phase. HDC is the first approved therapeutic to target the state of immunosuppression in AML; further development in this area may comprise supplementary or alternative counter-suppressive agents with the aim to improve the efficacy of cancer immunotherapy.
|
|
10. |
|
|